Arch oncology advances anti-cd47 antibody ao-176 into chemotherapy combination phase 1/2 trial in solid tumors

Arch oncology, inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-cd47 antibody therapies, today announce

ARCH Ratings Summary

ARCH Quant Ranking